SDC1 and plasma cell myeloma: In a different study, employing human myeloma cell lines and patient-derived CD138+ cells, the authors compared gene expression patterns between innate proteasome inhibitor-sensitive and proteasome inhibitor-resistant myeloma cells following test dosing with the second-generation proteasome inhibitor IXZ.